MX2022003531A - Polipeptidos de fusion dap10/dap12. - Google Patents
Polipeptidos de fusion dap10/dap12.Info
- Publication number
- MX2022003531A MX2022003531A MX2022003531A MX2022003531A MX2022003531A MX 2022003531 A MX2022003531 A MX 2022003531A MX 2022003531 A MX2022003531 A MX 2022003531A MX 2022003531 A MX2022003531 A MX 2022003531A MX 2022003531 A MX2022003531 A MX 2022003531A
- Authority
- MX
- Mexico
- Prior art keywords
- dap10
- fusion polypeptides
- dap12
- dap12 fusion
- dnax
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 230000004927 fusion Effects 0.000 title abstract 2
- 101150090209 HCST gene Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/464468—Mesothelin [MSLN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/55—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta invención se refiere a polipéptidos de fusión que comprenden un polipéptido de proteína 10 activadora de DNAX (DAP10) y un polipéptido de proteína 12 activadora de DNAX (DAP12). La exposición también se refiere a células que comprenden tales proteínas de fusión y su uso en el tratamiento del cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201913697A GB201913697D0 (en) | 2019-09-23 | 2019-09-23 | DAP10/DAP12 fusion polypeptides |
PCT/EP2020/076566 WO2021058563A1 (en) | 2019-09-23 | 2020-09-23 | Dap10/dap12 fusion polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022003531A true MX2022003531A (es) | 2022-07-11 |
Family
ID=68425491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022003531A MX2022003531A (es) | 2019-09-23 | 2020-09-23 | Polipeptidos de fusion dap10/dap12. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220332788A1 (es) |
EP (1) | EP4034555A1 (es) |
JP (1) | JP2022550485A (es) |
KR (1) | KR20220069025A (es) |
CN (1) | CN114729027A (es) |
AU (1) | AU2020352574A1 (es) |
BR (1) | BR112022005426A2 (es) |
CA (1) | CA3155168A1 (es) |
GB (1) | GB201913697D0 (es) |
IL (1) | IL291493A (es) |
MX (1) | MX2022003531A (es) |
WO (1) | WO2021058563A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230372485A1 (en) | 2021-11-15 | 2023-11-23 | Neogene Therapeutics B.V. | Engineered t cells with reduced tgf-beta receptor signaling |
GB202214120D0 (en) * | 2022-09-27 | 2022-11-09 | King S College London | Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
CN1292655C (zh) | 2001-11-08 | 2007-01-03 | 蛋白质设计实验室股份有限公司 | IgG抗体稳定的液态药物制剂 |
PE20071063A1 (es) | 2005-12-20 | 2007-10-24 | Bristol Myers Squibb Co | Formulaciones de proteinas estables |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
JP6849600B6 (ja) * | 2015-01-29 | 2021-06-30 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | キメラ抗原受容体、組成物及び方法 |
EP3697809A1 (en) * | 2017-10-20 | 2020-08-26 | Institut Curie | Dap10/12 based cars adapted for rush |
KR102226918B1 (ko) | 2018-03-23 | 2021-03-11 | 주식회사 에스엘바이젠 | 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도 |
-
2019
- 2019-09-23 GB GB201913697A patent/GB201913697D0/en not_active Ceased
-
2020
- 2020-09-23 CN CN202080079564.2A patent/CN114729027A/zh active Pending
- 2020-09-23 JP JP2022543798A patent/JP2022550485A/ja active Pending
- 2020-09-23 US US17/762,657 patent/US20220332788A1/en active Pending
- 2020-09-23 KR KR1020227011676A patent/KR20220069025A/ko active Search and Examination
- 2020-09-23 AU AU2020352574A patent/AU2020352574A1/en active Pending
- 2020-09-23 WO PCT/EP2020/076566 patent/WO2021058563A1/en unknown
- 2020-09-23 BR BR112022005426A patent/BR112022005426A2/pt unknown
- 2020-09-23 EP EP20788997.3A patent/EP4034555A1/en active Pending
- 2020-09-23 MX MX2022003531A patent/MX2022003531A/es unknown
- 2020-09-23 CA CA3155168A patent/CA3155168A1/en active Pending
-
2022
- 2022-03-20 IL IL291493A patent/IL291493A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20220332788A1 (en) | 2022-10-20 |
BR112022005426A2 (pt) | 2022-06-21 |
WO2021058563A1 (en) | 2021-04-01 |
AU2020352574A1 (en) | 2022-04-21 |
GB201913697D0 (en) | 2019-11-06 |
IL291493A (en) | 2022-05-01 |
CA3155168A1 (en) | 2021-04-01 |
CN114729027A (zh) | 2022-07-08 |
EP4034555A1 (en) | 2022-08-03 |
JP2022550485A (ja) | 2022-12-01 |
KR20220069025A (ko) | 2022-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020014285A3 (en) | Fusion constructs and methods of using thereof | |
MX2021000047A (es) | Proteina de fusion variante pd1-4-1bbl y procedimientos de uso de la misma. | |
GEP20237480B (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
PH12020551391A1 (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
MX2022001134A (es) | Proteinas quimericas de factor viii y usos de estas. | |
PL397167A1 (pl) | Przeciwnowotworowe bialko fuzyjne | |
MY191030A (en) | Gdf15 fusion proteins and uses thereof | |
SG10201806693XA (en) | Anti-myostatin antibodies and methods of use | |
ATE416190T1 (de) | Polypeptide mit bindungsaffinität für her2 | |
MX2021003765A (es) | Proteínas il-12 de fusión a fc heterodimérico. | |
MX2021000263A (es) | Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma. | |
MX2022001422A (es) | Proteinas de union a antigeno que se unen especificamente a mage-a. | |
MX2022003531A (es) | Polipeptidos de fusion dap10/dap12. | |
PH12021550885A1 (en) | Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof | |
MX2021000030A (es) | Metodos y composiciones que utilizan polipeptidos variantes klotho. | |
MX2021011726A (es) | Escindasas modificadas, usos de las mismas y kits relacionados. | |
MX2020002921A (es) | Anticuerpos para claudin6 y métodos para tratar el cáncer. | |
EP4273233A3 (en) | Mr1 restricted t cell receptors for cancer immunotherapy | |
EA202190240A1 (ru) | Варианты рекомбинантного белка | |
PH12017502213A1 (en) | Compositions and methods for treating celiac sprue disease | |
MX2022000367A (es) | Heterodimeros, metodos y uso de los mismos. | |
MX2021004188A (es) | Composiciones polipeptídicas estabilizadas con enlace disulfuro y métodos de uso. | |
WO2020117778A3 (en) | Reagents and methods for controlling protein function and interaction | |
EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
CL2017000200A1 (es) | Célula huésped mejorada para producir proteinas |